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Transdifferentiation of lung adenocarcinoma in
mice with Lkb1 deﬁciency to squamous cell
carcinoma
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Lineage transition in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) of
non-small cell lung cancer, as implicated by clinical observation of mixed ADC and SCC
pathologies in adenosquamous cell carcinoma, remains a fundamental yet unsolved question.
Here we provide in vivo evidence showing the transdifferentiation of lung cancer from ADC to
SCC in mice: Lkb1-deﬁcient lung ADC progressively transdifferentiates into SCC, via a
pathologically mixed mAd-SCC intermediate. We ﬁnd that reduction of lysyl oxidase (Lox) in
Lkb1-deﬁcient lung ADC decreases collagen disposition and triggers extracellular matrix
remodelling and upregulates p63 expression, a SCC lineage survival oncogene. Pharmaco-
logical Lox inhibition promotes the transdifferentiation, whereas ectopic Lox expression
signiﬁcantly inhibits this process. Notably, ADC and SCC show differential responses to Lox
inhibition. Collectively, our ﬁndings demonstrate the de novo transdifferentiation of lung ADC
to SCC in mice and provide mechanistic insight that may have important implications for lung
cancer treatment.
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L
ung cancer is one of the most devastating diseases worldwide
with high mortality1. As the major lung cancer type, non-
small cell lung cancer (NSCLC) is further characterized
by a high degree of histopathological heterogeneity including
adenocarcinoma (ADC, B48%), squamous cell carcinoma
(SCC, B28%) and large cell carcinoma (B24%)2,3. Based on
histopathological appearance and gene expression signature, it is
widely speculated that these cancer subtypes arise from distinct
cells of origin, for example, ADC is considered to arise mainly
from alveolar epithelial cells such as type II pneumocyte, whereas
SCC is from basal cells4,5. Accordingly, ADC mainly expresses
type II pneumocyte marker pro-surfactant protein C (SP-C), and
SCC expresses basal cell markers Trp63 (p63) and Cytokeratin
5/14 (Krt5/14)6,7. However, deﬁnitive evidence is not yet available
in order to identify the cells of origin for either lung ADC or SCC.
The mixed ADC and SCC pathology with identical genetic
mutations has been frequently observed in a single lesion of
human lung tumours, so called adenosquamous cell carcinoma
(Ad-SCC)8–11, suggesting a monoclonality and the potential
lineage transition between these subtypes. Whether there exist
lineage correlation or dynamic transition between lung ADC and
SCC in Ad-SCC is a fundamental yet unsolved question, not only
important for a better understanding of lung cancer biology but
also potentially helpful for lung cancer therapies in clinic.
However, the paucity of matched clinical specimens at different
stages from same patients makes it difﬁcult to examine the
dynamic transition of lung cancer; instead, this could be beneﬁted
from studies in genetically engineered mouse models of
human lung cancer12. The tumour suppressor LKB1 encodes an
evolutionarily conserved serine/threonine kinase essential for
both cellular growth and metabolic homoeostasis13–15. Loss-of-
function mutations of LKB1 have been observed in human lung
ADC, SCC and Ad-SCC specimens16,17. Interestingly, both
lung ADC and SCC with typical pathologies were consistently
observed in KrasG12D, Lkb1L/L (Kras/Lkb1) mouse model16. It’s
worth noting that the observation of lung SCC is quite unique
to Kras/Lkb1 mouse model since no squamous lesion but only
ADC has been observed in other models including Kras, Egfr and
Kras/p53 mouse models3,12,16,18. However, it remains unknown
how SCC arises in Kras/Lkb1 mouse model.
Through lineage-tracing experiments and pathological analyses
in Lkb1-deﬁcient mouse models of human lung cancer, we here
show that mouse lung ADC can transdifferentiate into SCC,
progressively via pathologically mixed adenosquamous cell
carcinoma as an intermediate. We ﬁnd that hypoxia deregulation
in Lkb1-deﬁcent ADC results in the decrease of Lox expression as
well as collagen deposition, and initiates extracellular matrix
(ECM) remodelling and turns on squamous signature gene
expression, which upregulates p63 expression. Interfering col-
lagen maturation in Kras/Lkb1 mice promotes ADC to SCC
transdifferentiation, while ectopic Lox expression signiﬁcantly
inhibits this process. Further studies show that pharmacological
inhibition of Lox effectively suppresses the progression of
Lkb1-deﬁcient ADC and promotes ADC to transdifferentiate
into SCC, but has little effects upon the growth of SCC. These
ﬁndings provide mechanistic insight into lung ADC to SCC
transdifferentiation in mice and may have implications for future
lung cancer treatment.
Results
ADC to SCC transdifferentiation in Kras/Lkb1 mouse model.
We ﬁrst carefully monitored the progression of different subtypes
of lung tumours in a group of Kras/Lkb1 mice treated with
recombinant adenovirus expressing Cre recombinase (Ad-Cre).
These mice were killed for histopathological analyses at a series of
time points post Ad-Cre infection. At as early as 2 weeks post
Ad-Cre treatment, atypical adenomatous hyperplasia (AAH) and
epithelial hyperplasia were observed as the dominant types of
lesions (Fig. 1a and Supplementary Fig. 1a). At 6 weeks post
Ad-Cre treatment, papillary adenoma and ADC were evident
(Fig. 1a,b; Supplementary Fig. 1a). Although caution is warranted,
at this stage we didn’t detect any obvious squamous lesion
by pathological inspection, immunohistochemical staining
and statistical analyses of SCC marker Trp63 (p63) (Fig. 1b;
Supplementary Fig. 1b,c). Only after 8 weeks of Ad-Cre treat-
ment, we began to observe very few typical SCCs with big tumour
sizes among a wide spectrum of lesions composed of AAH,
epithelial hyperplasia, adenoma and ADC (Fig 1a,b). At an even
longer time (12 weeks) post Ad-Cre treatment, the number of
SCC increased concomitantly with a decrease of ADC number,
while the total tumour number showed no signiﬁcant change
(Fig. 1b). Consistent with our previous study, local metastasis was
detected in 3 of 19 (16%) mice at 10–12 weeks post Ad-Cre
treatment and all these tumours were ADC.
Although SCC appeared at a much later time point than ADC,
the average tumour size of SCC was evidently bigger than that of
ADC (Fig. 1c,d). It is more likely that these abruptly appearing
SCCs are developed from those ADCs at late time point.
To further conﬁrm this, we dissected primary tumours from
Kras/Lkb1 mice at 6 weeks post Ad-Cre infection, with part of
them for serial transplantation experiments in three nude mice
(Supplementary Fig. 1d), and the remaining parts for pathological
and immunohistological analysis. The dissected tumours were
conﬁrmed as ADC without any p63-positive cells revealed by
immunohistological and statistical analysis on serial sections.
Interestingly, we were able to detect SCC derived from one out of
three ADC with typical squamous morphology at later passage
(passage 3), despite the initial Ttf1-expressing ADC pathology at
early passages (passages 1–2) (Supplementary Fig. 1e,f).
As in our previous study16, apart from those typical SCC
we consistently observed a portion of mixed lesions with
adenomatous and squamous pathologies in Kras/Lkb1 mice at
8–12 weeks post Ad-Cre treatment. These mixed lesions
morphologically resembled the adenosquamous cell carcinoma
observed in the clinic8–11, and were featured with a majority of
p63-positive cells in proximity to SP-C-positive cells in a single
tumour lesion (Fig. 1e). We henceforth arbitrarily deﬁned these
mixed lesions as mouse adenosquamous cell carcinoma (mAd-
SCC), although most of them mainly contained squamous
histology with a small part of ADC. At 8–10 weeks post
Ad-Cre treatment, B70% of squamous lesions were mAd-SCC.
However, the percentage of mAd-SCC gradually decreased to
B30% at 10–12 weeks post Ad-Cre treatment, and to only 10%
post an even longer time treatment (12–14 weeks). On the
contrary, the percentage of typical SCC without mixed ADC
pathology increased with time (Fig. 1f). Consistently, statistical
analysis revealed that the average percentage of p63-positive cells
progressively increased from 66 to 92% concomitantly with a
decrease of average percentage of cells positive for SP-C from 34
to 8% in mAd-SCC from 8 to 12 weeks post Ad-Cre treatment
(Supplementary Fig. 1g,h). Collectively, these data suggest that
LKB1-deﬁcient ADC progressively transdifferentiate into SCC via
a pathologically mixed intermediate as mAd-SCC.
ADC from type II pneumocyte transdifferentiates into SCC.
Recent lineage-tracing experiments in mice have identiﬁed type II
pneumocytes, Clara cells in the terminal bronchioles and putative
bronchoalveolar stem cells as cells of origin for Kras-induced lung
hyperplasia, and only type II cells appear to progress to ADC19.
To further conﬁrm ADC to SCC transdifferentiation in vivo, we
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performed lineage-tracing experiments in LKB1-deﬁcient mouse
models. Based on the fact that mouse lung ADC is mainly derived
from type II pneumocyte4,5, we constructed a mouse allele (SP-C-
CreERT2) using human SP-C promoter to drive CreERT2
expression speciﬁcally in this deﬁned lineage20,21. We ﬁrst
examined the speciﬁcity as well as functionality of the SP-C
promoter in SP-C-CreERT2/Rosa26R-LacZ mice. In the SP-C-
CreERT2/Rosa26R-LacZ mice, we found that tamoxifen-induced
LacZ expression from Rosa26 locus was speciﬁcally restricted to
SP-C-positive type II pneumocytes, but not in basal cells that are
Sox2-positive22 (Fig. 2a; Supplementary Fig. 2a,b); We then
crossed SP-C-CreERT2 and SP-C-CreERT2, Rosa26R-LacZ mice
with Kras/Lkb1 mice to obtain a cohort of SP-C-CreERT2/Kras/
Lkb1 (SKL) and SP-C-CreERT2/Rosa26R-LacZ/Kras/Lkb1 (SRKL)
mice, respectively. In comparison with Kras/Lkb1 model, the SKL
mice after tamoxifen administration displayed a slow but
comparable kinetic of tumour progression (Supplementary
Fig. 2c). At 4–8 weeks post tamoxifen administration, a large
proportion of type II pneumocytes were targeted by CreERT2
activation and stained positive for SP-C with a progressive
process from AAH, adenoma, to ADC, whereas no p63-positive
SCC lesion was detectable yet (Supplementary Fig. 2d,e). As
expected, lung ADC was detected with positive X-gal staining
(Supplementary Fig. 2f), indicating that most if not all ADC in
SKL model were derived from SP-C-positive lineages. At 9–12
weeks post tamoxifen administration, the number of ADC
increased, and a few typical SCC began to appear (Fig. 2b). At
a longer time (13–16 weeks) post tamoxifen administration, the
number of SCC increased signiﬁcantly while that of ADC
decreased (Fig. 2b). The SCC was positive for X-gal staining,
highlighting their primary origin of ADC (Supplementary Fig. 2f).
Moreover, the SCC had larger tumour size than ADC (Fig. 2c,d),
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Figure 1 | Lkb1-deﬁcient Lung ADC progressively transdifferentiates into SCC. (a) Representative histology for AAH, adenoma, ADC and SCC
lesions in Kras/Lkb1 mice at a serial of time points post Ad-Cre treatment. Scale bar, 150mm. (b,c) Quantiﬁcation of average tumour number (b) and
tumour size (c) per mouse for ADC and SCC in Kras/Lkb1 mice at 6 weeks (n¼6), 8 weeks (n¼ 12) and 12 weeks (n¼8) post Ad-Cre treatment.
Data are shown as mean±s.e.m. t-test, *Po0.05, **Po0.01, ***Po0.001. (d) Quantiﬁcation of individual tumour size for ADC and SCC in Kras/Lkb1
mice at 10–12 weeks post Ad-Cre treatment. n¼ 12, Data are shown as mean±s.e.m. t-test, *Po0.05, **Po0.01, ***Po0.001. (e) Representative
mAd-SCC shown with haematoxylin and eosin staining, p63 and SP-C immunohistochemical staining on serial sections. Scale bar, 150mm.
(f) Quantiﬁcation of tumour percentage for mAd-SCC and SCC in Kras/Lkb1 mice at indicated time points post Ad-Cre treatment. n¼8 for each
time point. Scale bar, 150mm. Data are shown as mean±s.e.m. t-test, *Po0.05, **Po0.01, ***Po0.001.
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consistent with the observation from the Kras/Lkb1 mouse model
(Fig. 1c,d). Further detailed analyses revealed that the ratio of
mAd-SCC to SCC gradually decreased from 9 to 16 weeks post
tamoxifen administration (Supplementary Fig. 2g,h). We further
characterized the transdifferentiation process using p63 and SP-C
immunohistostaining combined with statistical analyses on
tumours from SKL mice at different time points. The average
percentage of p63-positive cells progressively increased from 82
to 92% concomitantly with a decrease of average percentage of
cells positive for SP-C from 18 to 8% in mAd-SCC from 9–12 to
13–16 weeks post tamoxifen treatment (Supplementary Fig. 2i,j),
indicating the gradual progress of transdifferentiation from ADC
into SCC through mAd-SCC as the intermediate. Together, our
data from three different animal models consistently support
de novo ADC to SCC transdifferentiation.
ECM remodelling in ADC to SCC transdifferentiation. To gain
mechanistic insights into ADC to SCC transdifferentiation pro-
cess, we performed bioinformatic analysis on the gene expression
proﬁles of LKB1-deﬁcient mouse ADC and SCC from our pre-
vious study16, to search for those signiﬁcantly deregulated
signalling pathways. Notably, the 20 signalling pathways
identiﬁed are mainly involved in cell–cell interaction and ECM
remodelling process (Fig. 3a and Supplementary Table 1). We
then randomly selected and compared several established gene
signatures related to these pathways23,24. Among these, there was
an increase of genes associated with cell junctions in SCC relative
to ADC, which include those participating in desmosome (Pkp1,
Pkp3, Dsc2, Dsc3, Dsg2, Dsp, Jup and Perp), tight junction (Cldn4,
Cldn7, Cldn8 and Cldn23) and gap junction (Gjb2 and Gjb3)
(Fig. 3b and Supplementary Table 2). Besides, several genes
involved in ECM degradation (Mmp9 and Mmp14) were
signiﬁcantly upregulated in SCC, and certain matrix metallo-
proteinase (MMP) inhibitors (Timp2, Timp3 and Timp4) were
downregulated (Fig. 3b and Supplementary Table 2). In
particular, several genes of collagen family essential for ECM
homoeostasis were also robustly decreased in SCC (Fig. 3b and
Supplementary Table 2). Independent validation using real-time
PCR analyses conﬁrmed the changes of most gene signatures
(Supplementary Fig. 3).
Even though the Kras activation and Lkb1 inactivation were
initially engineered in our mouse models, it is unlikely to exclude
the occurrence of new mutations in the mature tumours, which
may confound our observation of transdifferentiation process.
We then sequenced the genes of p53, PIK3CA, p16, Cul3, Nrf2,
Keap1 and p19 in 4 lung ADCs and 4 SCCs derived from
Kras/Lkb1 mice (primers are decribed in Supplementary Table 3),
because the mutations of these genes have been reported in
human lung SCC25. However, no mutation was detected for these
genes in both ADC and SCC.
LOX promotes ECM assembly by covalent intra- or inter-
molecular crosslinking of collagen via oxidatively deaminating
speciﬁc lysine and hydroxylysine residues in the telopeptide
domains26. Elevated expression of LOX, frequently observed in
several epithelial tumours, including breast cancer as well as
head and neck cancer, promotes cancer progression and
metastasis27–29. However, our bioinformatic analysis revealed
that Lox was robustly downregulated in SCC relative to ADC in
Kras/Lkb1 mice (Fig. 3b and Supplementary Table 2). Consistent
with less collagen deposition (Fig. 3c), we found that Lox mRNA
levels decreased in SCC when compared with ADC (Fig. 3d).
Indeed, expression of Lox could be detected in most of dissected
ADC but not in SCC as shown by western blotting analysis
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Figure 2 | Type II pneumocyte lineage-derived lung ADC with Lkb1 deﬁciency transdifferentiates into SCC. (a) Representative photos for SP-C and
X-gal double staining in lung sections of SP-C-CreERT2/Rosa26R-LacZ mice at 2 weeks post tamoxifen administration. Scale bar, 10mm. (b,c) Quantiﬁcation
of average tumour number (b) and tumour size (c) per mouse for ADC and SCC in SP-C-CreERT2/Kras/Lkb1 (SKL) mice at 4–8 weeks (n¼ 8), 9–12 weeks
(n¼8), 13–16 weeks (n¼ 10) post tamoxifen administration. Data are shown as mean±s.e.m. t-test, **Po0.01, ***Po0.001. (d) Quantiﬁcation of
individual tumour size for ADC and SCC in SKL mice at 12 weeks post tamoxifen administration (n¼ 6). Data are shown as mean±s.e.m. t-test,
***Po0.001. (e) Representative SCC in SKL mice with haematoxylin and eosin staining and immunohistochemical staining for p63, Krt5, Sox2 and
SP-C. Scale bar, 10mm.
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(Fig. 3e). To determine whether such patterns of LOX expression
and the collagen deposition are present in human lung cancer
samples, we analysed 85 human lung ADCs and 85 SCCs on
tissue microarray. Interestingly, we found that most of human
lung SCCs showed low or negative Lox expression as well as
collagen deposition compared with lung ADCs (Supplementary
Fig. 4).
Studies using regular sequencing or deep sequencing of
genomic DNA show that LKB1 inactivating mutations are
frequently observed in B20% of human ADC but only B2%
SCC25,30–32. Since LKB1 genetic alteration involves point
mutation as well as exonic deletion, we have previously
identiﬁed B19% (8/42) of human lung SCC with LKB1 genetic
alterations by the combination of direct sequencing and
molecular analysis with multiplex ligation-dependent probe
ampliﬁcation (MLPA) analysis of genomic DNA16. Indeed,
exonic deletion of LKB1 or even loss of whole gene allele
cannot be detected by either regular sequencing or deep
sequencing of genomic DNA due to the normal tissue
contamination during the PCR process. Using the same
method, we analysed another ethnically different cohort with
101 Chinese lung SCC samples and identiﬁed B13% (13 of 101)
of Chinese squamous cell carcinoma with LKB1 exonic deletions
plus 5% (5 of 101) patients harbouring LKB1 F354L mutation,
which has been indicated as an inactivating mutation33,34
(Supplementary Table 4).
We next studied how Lox was downregulated in Lkb1-deﬁcient
mouse SCC. We recently found that upregulated Lox expression
through activation of mTOR–Hif1a signalling axis correlates with
Lkb1 inactivation status and triggers excessive collagen deposition
in Lkb1-deﬁcient lung ADC to enhance tumour cell proliferation
and invasion35. We thus compared the hypoxia level in ADC and
SCC and found the hypoxia level was dramatically decreased in
SCC at 8 weeks post Ad-Cre treatment (Fig. 4a). To test whether
the change of hypoxia level contributes to the ADC to SCC
transdifferentiation, we crossed Hif2a mice with Kras/Lkb1
mice to functionally conﬁrm the effect of hypoxia level on
the transdifferentiation process36,37. After 10 weeks Ad-Cre
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Kras/Lkb1 mice. Scale bar, 50mm. (d) Real-time PCR detection of mRNA levels for p63, SP-C and Lox in lung ADC (n¼8) and SCC (n¼8) from Kras/Lkb1
mice. Data are shown as mean±s.e.m. t-test, *Po0.05, **Po0.01. (e) Western blot detection of protein levels for p63, SP-C and Lox in lung ADC
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treatment, Kras/Lkb1/Hif2a mice and Kras/Lkb1 mice were
histopathologically and statistically analysed. Activation of
Hif2a in Kras/Lkb1 mice dramatically inhibited the trans-
differentiation process, as shown of the decrease of SCC
number compared with control group (Fig. 4b,c). These data
demonstrated that hypoxia deregulation play a causative role in
the ADC to SCC transdifferentiation process.
As indicated by the association of the signiﬁcantly deregulated
pathways and gene signatures to ECM, we focused on the role of
LOX in ECM remodelling, although intracellular roles of LOX
were also documented38. To this, we infected Kras/Lkb1 mice
with lentivirus carrying Cre recombinase with or without the
dominant-negative minigene version of type I human procollagen
(MC) that inhibits collagen maturation and deposition (Lenti-Cre
and Lenti-Cre-MC)39,40, and analysed lung tumour formation at
13 weeks post treatment (Supplementary Fig. 5a)41,42. With a
relatively slower progression pattern than Ad-Cre treatment,
Lenti-Cre administration led to similar pathological phenotype,
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Figure 4 | Involvement of hypoxia and collagen deposition in ADC to SCC transdifferentiation. (a) Comparison of hypoxia levels in lung ADC and
SCC from Kras/Lkb1 mouse model. Scale bar, 150 mm. (b) Representative photos for haematoxylin and eosin and p63 immunohistochemical staining in
Kras/Lkb1 and Kras/Lkb1/Hif2a mice at 10 weeks post Ad-Cre treatment, Scale bar, 150mm. (c) Quantiﬁcation of average tumour number per mouse
for ADC and SCC from Kras/Lkb1 mice (n¼ 8) and Kras/Lkb1/Hif2a mice (n¼ 7). Data are shown as mean±s.e.m. t-test, **Po0.01. (d) Massons
Trichrome staining of lung ADC from Kras/Lkb1 mice virally infected by either Lenti-Cre or Lenti-Cre-MC. Scale bar, 150 mm. (e,f) Quantiﬁcation of
average tumour number per mouse for ADC and SCC (e) and mAd-SCC (f) from Kras/Lkb1 mice virally infected with Lenti-Cre (n¼8) or Lenti-Cre-MC
(n¼ 7). Data are shown as mean±s.e.m. t-test, *Po0.05, ***Po0.001. (g) Quantiﬁcation of average tumour size per mouse for ADC and SCC from
Kras/Lkb1 mice virally infected with Lenti-Cre (n¼ 8) or Lenti-Cre-MC (n¼ 7). Data are shown as mean±s.e.m.
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including ADC, mAd-SCC and typical SCC formation
(Supplementary Fig. 5b). Lenti-Cre-MC infection reduced
tumour collagen deposition and decreased the average number
and size of lung ADC (Fig. 4d,e,g), conﬁrming the positive role of
collagen deposition in lung ADC progression35. On the contrary,
the average number of SCC as well as Ad-SCC was increased by
Lenti-Cre-MC infection without signiﬁcant impact upon the
average SCC size (Fig. 4e–g), indicating an enhanced ADC to
SCC transdifferentiation. Together, these data suggest a role of
Lox downregulation in the ADC to SCC transdifferentiation
potentially through decreasing collagen deposition.
Lox overexpression inhibits ADC to SCC transdifferentiation.
To explore the role of Lox-mediated ECM remodelling in ADC to
SCC transdifferentiation, we ﬁrst tested the effect of ectopic Lox
expression upon this process. We infected Kras/Lkb1 mice with
lentivirus carrying Cre recombinase with or without Lox
expression (Lenti-Cre or Lenti-Cre-Lox), and compared the SCC
formation at 13 weeks post treatment (Fig. 5a). Consistent with
Ad-Cre treatment, Lenti-Cre administration led to similar
pathological phenotype, including ADC, Ad-SCC and typical
SCC formation. Lenti-Cre-Lox infection led to high expression of
Lox and increased collagen deposition in lung tumours (Fig. 5b).
Strikingly, only 27% (3/11) of mice in Lenti-Cre-Lox group
developed SCC, in contrast to 91% (10/11) of mice in Lenti-Cre
group with SCC post 13 weeks of viral treatment, indicating that
the incidence of SCC formation was signiﬁcantly inhibited by
ectopic Lox expression. Indeed, most tumours in Lenti-Cre-Lox
group were ADC and positive for SP-C staining (Supplementary
Fig. 6). Moreover, ectopic expression of Lox signiﬁcantly
decreased the number of SCC while increased that of ADC
(Fig. 5c,d), but had little effect upon average tumour size of either
subtype (Fig. 5e). These data demonstrated that ectopic Lox
expression inhibits ADC to SCC transdifferentiation potentially
through ECM remodelling.
Lox inhibition promotes ADC to SCC transdifferentiation. We
then performed pharmacological targeting of Lox enzymatic
activity to mimic Lox downregulation and investigated its impact
upon this process. We utilized b-aminoproprionitrile (BAPN), a
well-documented chemical that directly binds to the active site of
LOX and irreversibly inhibits its enzymatic activity to affect the
crosslinking of collagen molecules27,43–45. In our previous study,
we found that BAPN treatment for 8 weeks signiﬁcantly inhibited
the progression of Kras/Lkb1 ADC35. In this study, we herein
performed a shorter term of BAPN treatment (4 weeks) on
Kras/Lkb1 mice, with a focus on the transdifferentiation process
(Fig. 6a). As expected, BAPN treatment signiﬁcantly decreased
mouse serum Lox enzymatic activity and collagen deposition in
lung ADC (Supplementary Fig. 7a,b). Strikingly, we found that a
high percentage of BAPN-treated mice (86%, 12/14) developed
SCC, in contrast to only 17% (3/18) of control mice with
SCC (Table 1). The average number of SCC in BAPN-treated
mice signiﬁcantly increased with a concomitant decrease of
ADC number (Fig. 6b,c). Moreover, BAPN treatment increased
the average number of mAd-SCC (Fig. 5d), indicating the
acceleration of the transdifferentiation process. This is consistent
with the statistical analyses of the percentage of SP-C and/or
p63-positive cells (Supplementary Fig. 7c,d). However, we
observed no signiﬁcant effect of BAPN treatment upon the
average size of either tumour subtype (Fig. 6e,f). The essential role
of Lox in ADC to SCC transdifferentiation was further supported
by BAPN treatment in SKLmice, with lung tumours from deﬁned
cell lineage. The incidence of SCC formation was dramatically
increased by BAPN treatment, from 15% (3/20) to 60% (12/20)
(Supplementary Fig. 7f–i, Table 1).
We further used another chemical, D-penicillamine (DPA) to
inhibit Lox enzymatic activity. Different from BAPN, DPA
inhibits Lox function by chelating its cofactor copper46. DPA
treatment also resulted in a signiﬁcant decrease of serum
Lox enzymatic activity and collagen deposition in lung ADC
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(Supplementary Fig. 7a,b). We observed a promoter effect of DPA
upon ADC to SCC transdifferentiation, as 71% (10/14) of Kras/
Lkb1 mice harboured SCC post 4 weeks of DPA treatment
(Table 1). The number of ADC decreased signiﬁcantly, while the
number of SCC as well as mAd-SCC increased dramatically
(Supplementary Fig. 7j,k). No obvious change was found on the
tumour size of either ADC or SCC after DPA treatment
(Supplementary Fig. 7l,m).
Importantly, detailed immunohistological and statistical ana-
lyses revealed a decrease of cell proliferation with a concomitant
increase of cell apoptosis in certain ADC from Kras/Lkb1
mice after BAPN or DPA treatment in comparison with those
from control group (Supplementary Fig. 7n–q). However, no
signiﬁcant difference of either cell proliferation or apoptosis
was observed in SCC with or without Lox inhibition. Even with
BAPN or DPA treatment, these SCC still maintained a high rate
of cell proliferation and a low rate of apoptosis (Supplementary
Fig. 7n–q). These data reveal the different response of lung SCC
and ADC towards Lox inhibition and highlight an important
outcome of ADC to SCC transdifferentiation in drug resistance
development.
ECM remodelling regulates transdifferentiation through p63.
To further dissect the downstream effector of Lox-mediated ECM
remodelling in ADC to SCC transdifferentiation, we performed a
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Table 1 | Incidence of SCC formation in different mouse models after lox inhibition.
Genotype Treatment Time of treatment (weeks) After treatment (weeks) Incidence of SCCs P-value
Kras/Lkb1 Saline 3/18 (17%) o0.001
BAPN 4 4 12/14 (86%)
Kras/Lkb1 Saline 3/16 (18%) 0.003
DPA 4 4 10/14 (71%)
SP-C-CreERT2/Kras/Lkb1 Saline 3/20 (15%) 0.001
BAPN 6 3 12/20 (60%)
Statistical analyses were performed using Pearson w2 test.
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short term of BAPN treatment on Kras/Lkb1 mice. At as early as
2 weeks post BAPN treatment, apart from few typical SCC
lesions, we observed several lesions with typical ADC pathology
but with a few cells positive for p63 staining (Fig. 7a). In addition,
increased expression of p63 was also detected in BAPN-treated
subcutaneous tumours from human NSCLC cell line A549 in
nude mice (Fig. 7b). P63, especially the delta-N isoforms (DNp63)
act as master lineage survival oncogenes of SCC, and play
essential roles in epithelial stratiﬁcation and squamous cell sur-
vival47,48. We thus postulated that p63 activation is an essential
early step of the squamous transdifferentiation. Aiming to search
for potential p63 upstream regulators, we searched the literature
and then comparatively analysed mouse lung ADC and SCC
expression proﬁles, and identiﬁed a list of SCC signature genes
including Brf2, c-Myc, Dlx5, Klf5, Oct1, Sccro and Trim29.
Consistent with previous studies49–52, expression of these genes
was signiﬁcantly higher in mouse lung SCC than ADC
(Supplementary Fig. 8a), and a short term of BAPN treatment
increased the expression of most genes (c-Myc, Dlx5, Oct1, and
Sccro) in LKB1-deﬁcient mouse lung ADC (Fig. 7c). Interestingly,
individual expression of most genes (Brf2, c-Myc, Dlx5, Klf5, Sccro
and Trim29) upregulated p63 transcription in human NSCLC cell
lines (Fig. 7d). Since the Kras/p53 mouse model only produces
lung ADC12, we next tested whether ectopic p63 overexpression
can drive de novo squamous transdifferentiation from ADC in
Kras/p53 mouse model. We then established primary cell lines
from dissected Kras/p53 lung ADC, and performed DNp63a
overexpression in vitro followed by lung-seeding assays in nude
mice. Our data showed that transient DNp63a expression
in Kras/p53 cells activated Krt5 and Krt14 expression
(Supplementary Figs 8b,c and 9b), and cells with stable DNp63a
expression showed distinct morphologies from parental cells
(Supplementary Fig. 8d). Notably, apart from certain known p63
target genes (Krt5 and Krt14), DNp63a-expressing Kras/p53 cells
also expressed a series of genes previously identiﬁed as SCC
signature genes (Fig. 7e). In the lung-seeding assays in nude mice,
several tumours derived from DNp63a-expressing Kras/p53 ADC
cells were consistently found with SCC-like pathology, while
parental cells only gave rise to ADC pathology. Although stained
positive for squamous marker Krt5, these SCC-like tumours
still expressed ADC marker Ttf1, indicating a squamous
transdifferentiation process albeit incomplete (Fig. 7f). These
data demonstrate that ectopic expression of lineage survival
oncogene DNp63a is able to partially drive de novo ADC to SCC
transdifferentiation.
Discussion
Phenotypic plasticity and functional heterogeneity are important
features of tumours arising in various organs including the
lung25,53,54. Dissecting the potential phenotypic plasticity and
dynamic lineage correlation between tumour subtypes would
enable a better understanding of tumourigenesis and the
development of effective cancer therapeutic strategies. Recent
study showed that the glioblastoma stem cells are able to
transdifferentiate into endothelial cells55,56. The histopathological
heterogeneity of lung cancer has been established, and the
phenotypic plasticity between the tumour subtypes represents one
of the unsolved questions. Indeed, one recent study has revealed
the genotypic and histological transition of EGFR-mutant NSCLC
into SCLC after targeted therapy57. Notably, the transition from
neuroendocrine to mesenchymal phenotype could also be
achieved by ectopic expression of oncogenic RasV12 in SCLC58.
However, the linage transition of ADC and SCC remains
unknown. It is generally accepted that Kras-mutant ADC
originates mainly from the lineage of type II pneumocytes with
a stepwise progression from AAH to Adenoma, and then to
ADC3,41,59, while lung SCC potentially have different cells of
origin, possibly the basal cells4. Through detailed monitoring of
tumour progression patterns in three different mouse models,
we have here discovered a previously unexpected phenotypic
plasticity of lung ADC: lung ADC with LKB1 deﬁciency can
progressively transdifferentiate into SCC. Our data suggest that
the majority if not all of the cells in ADC with LKB1 deﬁciency
have the ability to transit to SCC. Moreover, the robust and
systematic transdifferentiation process occurs in a stage-speciﬁc
manner, different from traditional cancer stem cell theory in
which a minor cell population, such as glioblastoma stem cells,
was conferred with the phenotypic plasticity55,56. The transition
is also different from the metaplasia through cell replacement as
seen in PTEN-deﬁcient pancreatic ADC development in mice60.
Indeed, although we observed a statically signiﬁcant difference of
cell proliferating rate between ADC and SCC, these ADC cells
still keep proliferating despitea lower rate than SCC cells. In line
with this, we have identiﬁed the mixed pathology mAd-SCC as
the intermediate for this transition process. This work proves the
existence of lung ADC to SCC transdifferentiation in de novo
mouse models, highlighting the phenotypic plasticity of lung
ADC with LKB1 deﬁciency.
Initial analyses of gene signatures for cell junctions and ECM
homoeostasis, as wells as differential collagen deposition between
ADC and SCC, have indicated that LKB1-deﬁcient ADC might
depend more on ECM for survival and proliferation while SCC
depends more on cell–cell interactions instead. Indeed, inhibition
of collagen crosslinking by pharmacologically targeting Lox
signiﬁcantly suppresses ADC growth but has little effect upon
SCC. Thus, the different extents to which ADC and SCC depend
on ECM may reﬂect their differential sensitivity to ECM
perturbation. Beyond this, we have established an important
regulatory pathway for ECM in shaping phenotypic plasticity of
lung ADC with LKB1 deﬁciency: At the early stage, loss of the
tumour suppressor LKB1 promotes ADC progression partly
through Lox35; as the tumours grow up, Lox reduction following
reduced hypoxia level would lead to ECM remodelling, which
then results in the dramatic change so that the ADC cells
might robustly and systematically transit to SCC. The trans-
differentiation process would enable LKB1-deﬁcient ADC to
overcome the stress derived from ECM deﬁciency so that the
resultant SCC can keep growing at a high proliferation rate.
Moreover, more stress would be accumulated in LKB1-deﬁcient
ADC as they grow bigger. This may explain why we always
observed SCC with a large tumour size, even at their initial
appearances. A future challenge will be to decipher the identity
of stress and other potential mechanisms to unveil the
comprehensive molecular and cellular events in modulating
ADC to SCC transdifferentiation.
Our previous study suggested the LKB1 modulates lung
tumour initiation, differentiation and metastasis possibly through
independent mechanisms16. Consistently, ADC metastasis was
only observed after 10 weeks post Ad-Cre treatment, while ADC
to SCC transdifferentiation was observed at 8 weeks post Ad-Cre
treatment. We reason the phenotypic transition occurs earlier
than metastasis, and these two might be separate events during
tumour progression. Together with our previous ﬁndings35, we
unveil the dual function of Lox in LKB1-deﬁcient lung ADC,
one hand to promote ADC progression and metastasis35, the
other hand to inhibit ADC to SCC transdifferentiation via
ECM remodelling (the present study). Notably, Lox enzymatic
inhibition promotes LKB1-deﬁcient ADC transdifferentiation
into SCC, which then becomes insensitive to Lox inhibition.
Different from previously established molecular mechanisms
involved in drug resistance development, this may represent a
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unique and novel mechanism for escaping drug treatment at the
cellular level. Although this possibility remains to be tested
clinically, our study might provide helpful insights into
therapeutic strategy development for lung ADC in which
somatic LKB1 mutations are highly prevalent.
Methods
Mouse colony and tumour analyses. KrasG12D/p53L/L (Kras/p53), KrasG12D/
Lkb1L/L (Kras/Lkb1), and Rosa26-LacZ mice were originally provided by T. Jacks
(Cambridge, MA), R. DePinho (Boston) and L. Cheng (Shanghai), respectively.
All mice were housed in a pathogen-free environment at Shanghai Institute of
Biochemistry and Cell Biology and treated in accordance with protocols approved
by the Institutional Animal Care and Use Committee of the Shanghai Institute
of Biochemistry and Cell Biology, Chinese Academy of Sciences. To make the
SP-C-CreERT2 transgenic mice, a DNA fragment containing CreERT2-coding
region plus the SV40 poly A was ligated to the 3.7-kb region of the human
SP-C promoter20, and then microinjected into FVB/N blastocysts as described61.
Progeny were screened using Southern blot and conﬁrmed by PCR strategy. The
Kras/Lkb1 mice were treated with a low dosage of Ade-Cre (2 106 PFU), 60%
lower than the original dosage used in this model16, or Lentivirus (2 106 PFU) at
6–8 weeks of age via nasal inhalation as previously described3,16,35. Histological
examinations were performed by the pathologist Dr Yingyong Hou from
Zhongshan Hospital in Fudan University. For SP-C-CreERT2/Kras/Lkb1 (SKL) or
SP-C-CreERT2/Rosa26R-LacZ/Kras/Lkb1 (SRKL) mouse models, tamoxifen in
sunﬂower oil (40mg kg 1) were given to male mice at 6–8 weeks of age via
intraperitoneal injection every other day for ﬁve continuous doses. For
pharmacological treatment in Kras/Lkb1 mice, either BAPN (100mg kg 1),
DPA (150mg kg 1) or saline were given to mice at 4 weeks post Ad-Cre treatment
via intraperitoneal injection daily for 4 weeks. The SKL and SRKL mice at 6 weeks
post tamoxifen treatment were also administrated with BAPN for another 3 weeks.
For hypoxia probe treatment, mice were administrated with hypoxia probe solution
at a dosage of 1.5mg per mouse and 60 minutes later, the lungs were ﬁxed with 4%
paraformaldehyde for the preparation of routine parafﬁn section. After the
deparafﬁnization and hydration, the sections were incubated with 3% H2O2 in
distilled water and then in 10mM Citrate (pH¼ 6) for antigen retrieval. The
primary antibody (FITC-MAb1) and the secondary antibody (HRP linked to rabbit
anti-FITC IgG) were added and incubated at room temperature for 30min
respectively. Then DAB reaction, dehydration and mounting were performed as
usual. All mice were then killed for gross inspection and histopathological
examination. Tumour number was counted under microscope and tumour size was
analysed using Image J software35,61.
Nude mice experiments. Human NSCLC cell lines A549 and CRL5800 were
obtained from ATCC. Six-week-old male nude mice with BALB/c genetic
backgroud were used in the experiments. All mice were housed in a pathogen-free
environment at Shanghai Institute of Biochemistry and Cell Biology and treated in
strict accordance with protocols approved by the Institutional Animal Care and
Use Committee of the Shanghai Institute of Biochemistry and Cell Biology, Chinese
Academy of Sciences. For serial transplant experiment, three primary Kras/Lkb1
ADCs dissected from mice at 6 weeks post Adeno-Cre infection were divided into
two parts repectively: one part was homogenated and subcutaneously injected into
the nude mice (n¼ 3), and the other part was used for pathological inspection.
Once the tumours grew to 3–5mm in diameter (at least 1 month) in nude mice
(passage 1), these tumours were then dissected for continuous subcutaneous
xenografts for another two passages (the average duration for the second and third
passage is B3 weeks). The pathology was inspected for each passage. A549 cells
were subcutaneously injected into nude mice (5 106 cell per mouse) and BAPN
(100mg kg 1) or saline were given to mice 1 month later via intraperitoneal
injection daily for 4 weeks. For lung seeding assay, Kras/p53 cells were inoculated
into nude mice (2 106 cell per mouse) via tail vein injection, BAPN
(100mg kg 1) or saline were given to mice 1 month later via intraperitoneal
injection daily for 4 weeks. The tumours were harvested for histopathological
analysis and examined by a pathologist.
Histology and immunohistochemistry. Lungs from male and female mice were
inﬂated with 1ml 4% paraformaldehyde, ﬁxed overnight and dehydrated in
ethanol, embedded in parafﬁn, sectioned at 5 mm followed by staining with
haematoxylin and eosin. Immunohistochemistry was performed as previously
described16,35. The following antibodies were used: SP-C (AB3786, Chemicon;
1:2,000), Krt5 (BS1280, Bioworld, 1:200, 10 ng ml 1), p63 (SC-8431, Santa Cruz,
this antibody speciﬁcally recognizes DNp63; 1:200, 1 ng ul 1), Sox2 (AB5603,
Chemicon; 1:1,000, 1 ng ml), LOX (L4669, Sigma, 1:800, 1.25 ng ml 1), Ttf1
(5883-1, EPITOMICS; 1:500), Beta Galactosidase (ab9631, Abcam; 1:200). For
b-galactosidase staining, mouse lungs were isolated and immediately incubated for
2 h in a 20-fold volume of ice-cold ﬁxative (1% formaldehyde, 0.2% gluteraldehyde
and 0.02% NP40 in PBS) at 4C on a rolling platform. The ﬁxative was removed
and the tissues were washed twice in PBS for 20min at room temperature. The
galactosidase substrate (5mM K3Fe (CN)6, 5mM K4Fe (CN)6, 2mM MgCl2,
0.02% NP40, 0.1% sodium deoxycholate and 1mgml 1 X-gal in PBS) was then
added and the tissues were incubated in the dark overnight. The stained tissues
were transferred to tissue cassettes and ﬁxed overnight and dehydrated in ethanol,
embedded in parafﬁnand then sectioned at 5 mm for the following haematoxylin
and eosin staining and immunohistochemical staining62.
LOX enzymatic activity assay. Mouse sera were collected for LOX enzymatic
activity assessment35. Brieﬂy, samples were prepared in a ﬁnal volume of 1ml
containing 1.2M urea (Amresco), 0.05M sodium borate (Sigma, pH 8.2), 0.1 units
per ml of horseradish peroxidase (Fluka), 50 mM Amplex Red (Invitrogen) and
10mM 1, 5-diaminopentane (Sigma-Aldrich) and were incubated at 37 C for 1 h.
Fluorescence was measured using a Hitachi F-2000 ﬂuorescence spectrophotometer.
Parallel assays were prepared with 500mM BAPN to completely inhibit the activity of
LOX. The LOX activities were calculated as the increase in ﬂuorescent units above
the BAPN controls.
Establishment of primary mouse tumour cell line. Kras/p53 mice (male and
female at 6–8 weeks of age) were treated with Ade-Cre (2 106 PFU) via nasal
inhalation. Tumours were dissected after 10 weeks virus infection and cut into
small pieces and cultured in DMEM (Hyclone) supplemented with 10% FBS
(Biochrom). The medium was changed every other day until cells outgrew and
stable cell lines were formed.
Human lung cancer specimens collection. Human lung cancer specimens were
collected with the approval by the institutional review board of Shanghai Cancer
Hospital, Fudan University, Shanghai, China. All patients gave written informed
consent. Samples were snap-frozen in liquid nitrogen at the time of resection and
stored at  80 C until use. All cases were re-reviewed by pathologists for
conﬁrmation of tumour histology and tumour content. In the present study,
101 human lung SCC samples were used for exon sequencing and MLPA
experiments as described previously16. Human tissue microarray sections
containing 85 lung ADCs and 85 lung SCCs were immunohistochemically stained
with an anti-Lox antibody and performed with Massons Trichrome staining for
collagen deposition detection.
Lentivirus production and infection. The ORFs of Lox and DNp63a were
ampliﬁed from mouse tumour cDNAs, and ligated into expression vectors
pCDH-EF1-Puro (Systems Biosciences) or pCDH-EF1-Cre (adapted vector for Lox
expression in vivo). The production of lentivirus supernatant was described pre-
viously35,41. The human NSCLC cell lines A549 and CRL5800 (ATCC) were
maintained in RPMI1640 (Hyclone) supplemented with 10% FBS (Biochrom). For
transient overexpression, trypsinized cells were ﬁrst incubated with virus
supernatant (1:1 in volume) in a six-well plate (Corning) for 24 h, then cultured in
fresh medium for another 24 h, and harvested for analysis. For stable
overexpression of DNp63a, Kras/p53 ADC cells infected with virus were
persistently cultured in medium with puromycin (2 mgml 1, Sigma) until lung
seeding assays.
Western blotting and real-time PCR analyses. Lung tumours (Z2mm in
diameter) were freshly dissected from male and female Kras/Lkb1 mice at 8–10
weeks post Ad-Cre treatment. These tumours were immediately cut into several
pieces, one piece was used for HE and IHC inspection, and the rest pieces were
snap-frozen separately for western blotting and real-time PCR analyses. Western
blot assays were performed as previously described with antibodies against p63
(SC-8431, Santa Cruz, this antibody speciﬁcally recognizes DNp63; 1:200,
1 ngml 1), Lox (L4669, Sigma; 1:800, 1.25 ng ml 1), SP-C (AB3786, Chemicon;
1:2,000) and Actin (C-1, Santa Cruz; 1:2,000, 0.1 ng ml 1). Total RNA and genomic
DNA were prepared as previously described35. Total RNA was retrotranscribed
into ﬁrst-strand cDNA using RevertAid First Strand cDNA Synthesis Kit
(Fermentas). The cDNAs were then used for real-time PCR on a 7500 Fast
Real-Time PCR System (Applied Biosystems) using SYBR-Green Master PCR
mix (Toyobo). b-actin served as internal control. The primers for PCR were
summarized in Supplementary Information (Supplementary Table 5).
Microarray data analysis. Gene expression data (GEO accession: GSE6135)
generated in the previous study was preﬁltered using low stringency, pre-deﬁned
criteria: probe set intensity (432 in all samples) and dynamic variation (more than
twofold over the entire sample set)16. After ﬁltering, multiple probe sets that
presented the same genes were collapsed by taking the median value for that gene
per array yielding 3,275 unique genes, on which two-way hierarchical clustering
was performed. Gene expression microarray data were pre-processed with the
RMA algorithm63,64. To identify pathways altered in each sample, we ﬁrst
constructed a virtual reference sample by taking the median across all samples, and
then compared each sample with this reference to obtain twofold up- and
downregulated genes, which were further tested against a catalogue of biological
pathways with Fisher’s Exact Test. The pathways were collected from four public
databases: KEGG (www.genome.jp/kegg), Reactome (www.reactome.org), PID
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(pid.nci.nih.gov) and Wikipathways (wikipathways.org). Pathways witho15 genes
or 4500 genes were excluded for analyses. For each pathway, we calculated its
enrichment signiﬁcance in both up- and downregulated genes in the ith sample,
termed as pupi and p
down
i , respectively. In order to ﬁnd pathways with expression
patterns indicative of sample classes, here ADC and SCC, we summarized for each
pathway k an SL (signed minus log) score deﬁned as,
SLi;k ¼  1ð Þy log min pupi;k ; pdowni;k
  
; ð1Þ
where y is 1 if pupi;k  pdowni;k and 0 otherwise. Pathways showing poor enrichment
across samples (insigniﬁcant in more than half samples) were not included for
further analyses. We used the k-Nearest Neighbour (k-NN) method (ties broken
randomly) with leave-one-out cross validation to measure the accuracy of a
pathway in classifying samples. Note k was always optimally chosen by maximizing
the prediction accuracy. To achieve robust outcomes, we replicated the procedure
for a number of times (100 here) and took the average accuracy as the ﬁnal
measure. Pathways with 100% average accuracy were chosen for further
consideration. In the pathway-level heat map, colours were assigned according to
the SLi,k scores, whereas in the gene-level heat map, they were assigned according
to gene-wise standardized expressions.
Statistical analysis. Differences were compared using two-tailed Student’s t-test.
P-valueo0.05 was considered statistically signiﬁcant. All analyses were performed
with SPSS 16.0 (SPSS).
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